ABSTRACT
Fifty-five percent of patients with chronic myeloid leukaemia (CML) are aged 50 years or less at diagnosis.1 Of these, some 30% will have an HLA-identical sibling donor, and approximately two-thirds (11% of all patients) may be cured by allogeneic stem cell transplantation (SCT). Almost 90% of patients are therefore ineligible for, or do not benefit from, sibling SCT. There is an urgent need to extend the availability of SCT and to improve its outcome.
